Current possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus

Background. Cardiovascular morbidity increases notably among patients with diabetes. A correlation between leptin resistance and cardiovascular risk was found in arterial hypertension metabolic syndrome. However, there are no data about the influence of empagliflozin on level; effectiveness against key factors diabetic normal weight overweight has not been studied yet. The purpose this work to study impact comprehensive treatment using metformin main type 2 diabetes mellitus different body weights. Materials methods. Ninety-seven weight, obesity were examined. Anthropometric indicators taken. parameters carbohydrate lipid metabolism, level blood serum determined HOMA-IR calculated. Results. Insulin all groups associated abdominal obesity, hyperleptinemia (r=0.505, p<0.05; r=0.846, r=0.886, p<0.05 I–III). After a 6-month course empagliflozin, waist circumference significantly decreased obese patients, significant changes those mass index. reliable positive effect systolic pressure, regardless patient’s noted. Under use (p<0.05) also groups, Conclusions. It that combined for 6 months had modified